Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04462471
Title Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

thyroid gland follicular carcinoma

thyroid gland papillary carcinoma

Therapies

Copanlisib + Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST